Get the latest Science News and Discoveries
Why the FDA rejected a ‘breakthrough’ melanoma drug
The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other drug approvals
None
Or read this on Scientific American

